Published in Chem Biol Interact on January 01, 1977
Combined effects of chemotherapy and immunity against leukemia L1210 in DBA-2 mice. Cancer Res (1969) 1.26
Specific inhibition of the enzymic decarboxylation of S-adenosylmethionine by methylglyoxal bis(guanylhydrazone) and related substances. Biochem J (1974) 1.15
Inhibition of tumor cell growth in vitro and in vivo by 1-beta-D-arabinofuranosylcytosine entrapped within phospholipid vesicles. Cancer Res (1976) 1.12
Effects of methylglyoxal bis(ganylhydrazone) on trypanosomatid flagellates: inhibition of growth and nucleoside incorporation in Trypanosoma brucei. J Protozool (1978) 1.01
Prostaglandin modulation of development of cell-mediated immunity in culture. Nature (1980) 1.00
Evidence for the involvement of ecto-5'-nucleotidase (CD73) in drug resistance. Int J Cancer (1996) 0.99
Modification of tumor regression by immunologic means. Cancer Res (1969) 0.99
Role of tumor necrosis factor in macrophage activation and tumoricidal activity. Cancer Res (1988) 0.97
Effect of recombinant tumor necrosis factor on tumoricidal activation of murine macrophages: synergism between tumor necrosis factor and gamma-interferon. Cancer Res (1987) 0.93
Tumoricidal activation of murine resident peritoneal macrophages by interleukin 2 and tumor necrosis factor alpha. Cancer Res (1992) 0.91
The generality of methylglyoxal bis(guanylhydrazone)-induced mitochondrial damage and the dependence of this effect on cell proliferation. Cancer Res (1979) 0.90
Cell population kinetics of fast- and slow-growing transplantable tumors derived from spontaneous mammary tumors of the DBA/2 Ha-DD mouse. Cancer Res (1978) 0.89
Cellular basis for adriamycin-induced augmentation of cell-mediated cytotoxicity in culture. Cancer Res (1984) 0.89
Morphological evidence for an antimitochondrial action by methylglyoxal-bis(guanylhydrazone). Cancer Res (1977) 0.89
Role of tumor necrosis factor and interleukin 1 in gamma-interferon-promoted activation of mouse tumoricidal macrophages. Cancer Res (1989) 0.89
Adriamycin-induced modulation of host defenses in tumor-bearing mice. Cancer Res (1992) 0.88
Correlation of ultrastructural and functional damage to mitochondria of ascites L1210 cells treated in vivo with methylglyoxal-bis(guanylhydrazone) or ethidium bromide. Cancer Res (1979) 0.88
Ecto-5'-nucleotidase (CD73) in multidrug-resistant cell lines generated by doxorubicin. Int J Cancer (1994) 0.88
Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-beta-D-arabinofuranosylcytosine against mouse L1210 leukemia. Cancer Res (1979) 0.88
Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice. Cancer Res (1977) 0.88
Effects of anticancer drugs on the immune system in humans. Semin Oncol (1989) 0.88
Immunosuppressive effects of methylglyoxal-bis(guanylhydrazone) on mouse bone marrow and spleen cells and their antagonism by spermidine. Biochem Pharmacol (1978) 0.87
Toxicological and antiproliferative effects of N6-(delta2-isopentenyl) adenosine, a natural component of mammalian transfer RNA. Cancer Res (1970) 0.87
Protective specific immunity induced by doxorubicin plus TNF-alpha combination treatment of EL4 lymphoma-bearing C57BL/6 mice. Int J Cancer (2000) 0.87
Biologic-response modifiers and adjuvant chemotherapy: consideration of selected preclinical investigations in relation to clinical potential. Recent Results Cancer Res (1982) 0.87
Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in mice. Cancer Res (1986) 0.86
Use of liposomes for the enhancement of the cytotoxic effects of cytosine arabinoside. Ann N Y Acad Sci (1978) 0.86
A novel tumor necrosis factor-alpha inhibitory protein, TIP-B1. Int J Immunopharmacol (2000) 0.85
Modification of host antitumor defense mechanisms in mice by progressively growing tumor. Cancer Res (1989) 0.85
Doxorubicin-induced DNA degradation in murine thymocytes. Mol Pharmacol (1994) 0.85
Selective modulation by alpha-difluoromethylornithine of T-lymphocyte and antibody-mediated cytotoxic responses to mouse tumor allografts. Cancer Res (1986) 0.84
Doxorubicin plus tumor necrosis factor alpha combination treatments in EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunol Immunother (1998) 0.83
Expression, tissue distribution, and cellular localization of the antiapoptotic TIP-B1 protein. J Leukoc Biol (2001) 0.83
Fast- and slow-growing transplantable tumors derived from spontaneous mammary tumors of the DBA/2 Ha-DD mouse. Cancer Res (1975) 0.82
A selective effect of methylglyoxal-bis(guanylhydrazone) on the synthesis of mitochondrial DNA of cultured L1210 leukemia cells. Cancer Res (1979) 0.82
Effects of prostaglandins on the development of cell-mediated immunity in culture and on the cytolytic activity of in vivo-generated effector cells. Int J Immunopharmacol (1982) 0.81
Modulation of the development of cell-mediated immunity: possible role of the products of the cyclo-oxygenase and the lipoxygenase pathways of arachidonic acid metabolism. Int J Immunopharmacol (1982) 0.81
The clinical toxicity of anticancer drugs and its prediction. Semin Oncol (1977) 0.81
Adriamycin induced immunomodulation: dependence upon time of administration. Int J Immunopharmacol (1983) 0.81
Effect of splenectomy on the regression of transplantable tumors. Cancer Res (1968) 0.81
Alterations in murine host defense functions by adriamycin or liposome-encapsulated adriamycin. Cancer Res (1988) 0.81
Cyclophosphamide plus tumor necrosis factor-alpha chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma. Int J Cancer (1995) 0.80
Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2. Cancer Immunol Immunother (1996) 0.80
Antigenic differences between leukemia L1210 and a subline resistant to methylglyoxal-bis(guanylhydrazone). Cancer Res (1972) 0.80
Plasma membrane as a site for chemotherapeutic intervention. Adv Enzyme Regul (1978) 0.80
Comparative study of the toxicologic effects of 7-deazaadenosine (tubercidin) and 7-deazainosine. Cancer Res (1969) 0.79
Guanylhydrazones with potential antileukemic activity. 2. Synthesis and structure-activity relationships of analogues of 4,4'-diacetyl-N,N'-diphenylurea bis(guanylhydrazone). J Med Chem (1978) 0.79
Protective specific immunity induced by cyclophosphamide plus tumor necrosis factor alpha combination treatment of EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunol Immunother (1995) 0.79
A simple method for long-term drug infusion in mice: evaluation of guanazole as a model (38488). Proc Soc Exp Biol Med (1975) 0.79
Lipopolysaccharide and splenic tumoricidal macrophage activation. J Leukoc Biol (1994) 0.79
Toxic and patologic effects of 4,4'-diacetyl-diphenyl-urea-bis(guanylhydrazone), a new antileukemic agent. Cancer Res (1969) 0.79
Changes in cytosolic and membrane TNF inhibitory protein-B1 (TIP-B1) levels associated with protection from TNF-induced cytotoxicity. FASEB J (2001) 0.79
Comparison of adriamycin induced immunomodulation with that of the noncardiotoxic anthracycline 5-iminodaunorubicin. Int J Immunopharmacol (1988) 0.79
Thymic anti-tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF-alpha therapy: phenotypic and functional characterization up to 20 months after initial tumor inoculation. Int J Cancer (1998) 0.79
The effect of PS-K, a protein bound polysaccharide, on immune responses against allogeneic antigens. Int J Immunopharmacol (1983) 0.78
Polymyxin B-mediated lysis of tumor cells. Int Arch Allergy Immunol (1993) 0.78
Selective effects of Adriamycin on murine host defense systems. Immunol Rev (1982) 0.78
Induction of suppressor T cells in culture--I. Cell-cell interactions. Int J Immunopharmacol (1984) 0.78
Selection for high immunogenicity in drug-resistant sublines of murine lymphomas demonstrated by plaque assay. Cancer Res (1975) 0.78
Identification, characterization, and cloning of TIP-B1, a novel protein inhibitor of tumor necrosis factor-induced lysis. Cancer Res (1999) 0.78
Murine splenic macrophage tumoricidal activation by cytokines. Exp Hematol (1995) 0.78
Indomethacin modulation of adriamycin-induced effects on multiple cytolytic effector functions. Cancer Immunol Immunother (1990) 0.78
Evaluation of combination chemotherapy in vivo and in culture with l- -D-arabinofuranosylcytosine and 1-formylisoquinoline thiosemicarbazone. Cancer Res (1972) 0.78
Development of a safe and effective adriamycin plus interleukin 2 therapy against both adriamycin-sensitive and -resistant lymphomas. Oncol Res (1993) 0.78
Reversal of the in vitro methotrexate suppression of cell-mediated immune response by folinic acid and thymidine plus hypoxanthine. Cancer Res (1980) 0.77
Selectivity of inhibition by anticancer agents of mouse spleen immune effector functions involved in responses to sheep erythrocytes. Cancer Res (1978) 0.77
Suppression of hepatic lymphokine-activated killer cell induction by murine Kupffer cells and hepatocytes. Hepatology (1990) 0.77
Intracellular doxorubicin kinetics in lymphoma cells and lymphocytes infiltrating the tumor area in vivo: a flow cytometric study. Oncol Res (1994) 0.77
Anticancer drugs plus cytokines: immunodulation based therapies of mouse tumors. Int J Immunopharmacol (2000) 0.77
Doxorubicin and cyclosporin A affect murine lymphoid cells expressing different antigenic determinants. Oncol Res (1995) 0.77
In vitro effects of 4-hydroxyperoxycyclophosphamide on human immunoregulatory T subset function. Methods Find Exp Clin Pharmacol (1987) 0.77
Immunomodulating effects of anticancer drugs: the example of adriamycin. Transplant Proc (1984) 0.77